MAMSA RESISTANCE AND EXPRESION OF P76 PROTEIN
MAMSA 抗性和 P76 蛋白的表达
基本信息
- 批准号:3195940
- 负责人:
- 金额:$ 9.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1990
- 资助国家:美国
- 起止时间:1990-05-01 至 1993-04-30
- 项目状态:已结题
- 来源:
- 关键词:DNA topoisomerases acute leukemia antileukemic agent chemical structure function clone cells complementary DNA drug resistance gene expression genetic manipulation human subject laboratory mouse laboratory rabbit monoclonal antibody mutant myelogenous leukemia neoplasm /cancer genetics neoplastic cell neoplastic cell culture for noncancer research nucleic acid probes oligonucleotides pharmacogenetics protein structure function transfection
项目摘要
The objective of the proposed studies is to investigate potentially new
molecular and biochemical mechanisms of the resistance to intercalating
agent mAMSA, specifically the role of a protein with an apparent molecular
weight of 76,000 (p76), found to be consistantly associated with primary,
in vitro induced resistance to mAMSA in numerous independently derived
human acute myelogenous leukemia (AML) cell lines. We propose to use
recombinant DNA clones and antibodies to p76 as detection probes to relate
the function of p76 to mAMSA resistance in AML cell lines. After further
purification of the p76 to homogeneity we will determine amino acid
sequence of any internal peptides and also produce antibodies to p76.
Based on the amino acid sequence, a unique oligonucleotide probe will be
constructed and used to obtain full length cDNA corresponding to p76. The
isolated p76 cDNA will be transfected using a suitable vector into mAMSA
resistant mutants. The phenotype of transfected cells will be screened for
p76 expression using p76 antibodies; for drug sensitivity and for drug
induced changes in the Topoisomerase II activity. With the advent of the
described molecular probes and p76 antibodies we will screen leukemic
samples from AML patients in various stages of their disease i.e. prior
treatment and during the course of chemotherapy with mAMSA and emergence of
clinical resistance. The ultimate goal of the study is to clarify the role
of p76 in cellular response of leukemic cells to mAMSA and in the
development of mAMSA resistance, both in experimental models and clinical
situations.
拟议研究的目的是调查潜在的新
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MILOSLAV BERAN其他文献
MILOSLAV BERAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MILOSLAV BERAN', 18)}}的其他基金
MAMSA RESISTANCE AND EXPRESION OF P76 PROTEIN
MAMSA 抗性和 P76 蛋白的表达
- 批准号:
3195944 - 财政年份:1990
- 资助金额:
$ 9.62万 - 项目类别:
MAMSA RESISTANCE AND EXPRESION OF P76 PROTEIN
MAMSA 抗性和 P76 蛋白的表达
- 批准号:
3195943 - 财政年份:1990
- 资助金额:
$ 9.62万 - 项目类别:
相似海外基金
Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
- 批准号:
10655162 - 财政年份:2023
- 资助金额:
$ 9.62万 - 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
- 批准号:
10839678 - 财政年份:2023
- 资助金额:
$ 9.62万 - 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
- 批准号:
10651543 - 财政年份:2023
- 资助金额:
$ 9.62万 - 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
- 批准号:
10829603 - 财政年份:2023
- 资助金额:
$ 9.62万 - 项目类别:
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
预测儿童急性白血病甲氨蝶呤神经毒性的系统流行病学方法
- 批准号:
10655716 - 财政年份:2023
- 资助金额:
$ 9.62万 - 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
- 批准号:
10435886 - 财政年份:2022
- 资助金额:
$ 9.62万 - 项目类别:
mRNA stability and its impact on hematopoiesis and acute leukemia
mRNA稳定性及其对造血和急性白血病的影响
- 批准号:
10339742 - 财政年份:2022
- 资助金额:
$ 9.62万 - 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
- 批准号:
10505579 - 财政年份:2022
- 资助金额:
$ 9.62万 - 项目类别:
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemia
急性白血病微小残留病的克隆动力学和化疗耐药机制
- 批准号:
10351765 - 财政年份:2022
- 资助金额:
$ 9.62万 - 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
- 批准号:
10576955 - 财政年份:2022
- 资助金额:
$ 9.62万 - 项目类别: